In support of this role inhibiting DYRK1B in ovarian cancer cells was found to initiate apoptosis and to sensitize cancer cells to cisplatin (DNA damaging agent) [68], supporting the assumption that DYRK1B could act in a similar way in COAD. Here, DYRK1B is linked to ovarian carcinoma.